Navigation Links
Cephalon Statement on Federal Trade Commission Action Regarding PROVIGIL Patent Settlements
Date:2/13/2008

FRAZER, Pa., Feb. 13 /PRNewswire-FirstCall/ -- Cephalon, Inc., (Nasdaq: CEPH) issued the following statement in response to a complaint filed today by the U.S. Federal Trade Commission (FTC) in U.S. District Court for the District of Columbia challenging the validity of certain agreements entered into by the company in late 2005 and early 2006 to settle the PROVIGIL(R) (modafinil) [C-IV] patent infringement litigation and seeking to permanently enjoin the Company from maintaining or enforcing these agreements.

Cephalon stands by the strength and validity of our PROVIGIL patents and the legal basis for these settlements. We are disappointed that the FTC has determined to challenge these agreements as we believe they fully comply with both the spirit and letter of the antitrust laws. As importantly, our settlements confer a meaningful benefit to U.S. consumers by providing for the entry of generic modafinil three years early.

Cephalon is prepared to vigorously defend itself in this matter and expects to prevail.

About Cephalon, Inc.

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of innovative products in four core therapeutic areas: central nervous system, pain, oncology and addiction. A member of the Fortune 1000, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota. The company's European headquarters are located in Maisons-Alfort, France.

The company's proprietary products in the United States include: PROVIGIL, FENTORA(R) (fentanyl buccal tablet) [C-II], TRISENOX(R) (arsenic trioxide) injection, AMRIX(R) (cyclobenzaprine hydrochloride extended-release capsules), VIVITROL(R) (naltrexone fo
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cephalons 2007 Results Exceed Full Year Sales and Earnings Guidance
2. Cephalon General Counsel John E. Osborn to Resign Position
3. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
4. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
5. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
6. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Announces Strong Third Quarter Financial Results
9. Cephalon Quarterly Conference Call Invitation
10. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
11. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Grace Century portfolio project, Provia Laboratories , ... the Board, to the National Stem Cell Ethics Committee ... by the Ministry of Health on behalf of the Government ... More than a year after Bahamian Parliament passed the ... Christie said the government has completed the accompanying regulations and ...
(Date:10/30/2014)... , Oct. 30, 2014  Regado Biosciences, Inc. (Nasdaq: ... hold a conference call and live audio webcast on ... discuss its third quarter 2014 financial results. ... by dialing (888) 347-1165 for domestic callers or (412) ... webcast live under the investor relations section of the ...
(Date:10/27/2014)... 27, 2014 Ryan Carfley , Managing ... to sit down with Bryan Hamilton, the publisher of the ... discuss talent in the Research Triangle region of North Carolina. ... highlighted at the roundtable include the role of social ... of work/life balance and the unique role that Millennials play ...
(Date:10/27/2014)... and TORONTO , ... ( www.generex.com ) (OTCQB: GNBT) today announced two ... response triggered by its novel proprietary cancer immunotherapeutic ... in breast cancer patients. The AE37 cancer vaccine ... Antigen Express, Inc. ( www.antigenexpress.com ). The presentations ...
Breaking Biology Technology:Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 2Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 3Regado Biosciences to Provide Third Quarter 2014 Financial Results 2Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 2Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 4
... the price of soybean seed skyrocketing, soybean growers are looking for ... seeding rate. The research and education director of the North Central ... and profit potential in 2009. , ... Urbandale, Iowa ...
... (ASX: CYT) has today circulated a letter and ... shareholders. The letter provides an update on the ... 2009 and provides recommendations on how to vote ... 2009.(Photo: http://www.newscom.com/cgi-bin/prnh/20090225/NY75105 )The letter and the sample ...
... SEATTLE, Feb. 24 Implicit,Bioscience Ltd today announced ... Eli Lilly and Company. Implicit has paid an,undisclosed ... will also,receive a royalty on future IC14 sales. ... substantial expertise and passion to the,treatment of patients ...
Cached Biology Technology:NCSRP Research Director: "Earlier Planting can Increase Soybean Yields" 2NCSRP Research Director: "Earlier Planting can Increase Soybean Yields" 3Cytopia Letter to Progen Shareholders 2Cytopia Letter to Progen Shareholders 3Cytopia Letter to Progen Shareholders 4Cytopia Letter to Progen Shareholders 5Implicit Licenses Clinical Stage Antibody Program From Lilly 2Implicit Licenses Clinical Stage Antibody Program From Lilly 3
(Date:10/31/2014)... been studying the behavior of approximately 300 wild ... They observed that ravens slowly build alliances through ... they also observed that these affiliative interactions were ... about 50 % of the cases these interventions ... ravens, intervening can be potentially risky when the ...
(Date:10/30/2014)... Restoring wetlands can help reduce or reverse soil ... research in California,s Sacramento-San Joaquin River Delta by ... study, which is one of the first to ... methane as they cycle through wetlands, appears in ... . , Worldwide, agricultural drainage of organic ...
(Date:10/30/2014)... life, cells immediately begin accepting assignments to become a ... humans, are special. The cells of mammalian embryos get ... the protective placenta or to commit to forming the ... research from Michigan State University has revealed key discoveries. ... PLOS Genetics , provide insights into where ...
Breaking Biology News(10 mins):Dartmouth study finds restoring wetlands can lessen soil sinkage, greenhouse gas emissions 2Identifying the source of stem cells 2
... (NYSE: A) today introduced a high-performance ion trap ... life-science researchers to identify 60 to 80 percent ... such as protein identification and biomarker discovery, potentially ... cancer and speeding drug development efforts. The Agilent ...
... frequency of drug resistance in isolates of the AIDS ... urgent necessity. Host genes required to support the replication ... targets, but relatively few appropriate target genes have been ... conducted by Dr. Suzanne Sandmeyer and colleagues at the ...
... D. Anderson Cancer Center have developed a way to test ... chemotherapy drug Taxol are effectively killing tumor cells. They say ... to accurately assess whether patients are responding to these agents, ... , In two different studies being presented at the ...
Cached Biology News:Product improves peptide identification for proteomics research 2Study reveals candidate targets for anti-retroviral therapeutics 2Measuring Enzymes At End Of Cancer Pathway Predicts Outcome Of Tarceva, Taxol 2Measuring Enzymes At End Of Cancer Pathway Predicts Outcome Of Tarceva, Taxol 3
BD BioCoat Fibronectin 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of human fibronectin....
... a positive selection for creating baculovirus recombinants ... insect cells. The kit improves on the ... eliminating the time-consuming steps of plaque purification. ... with a portion of the essential open ...
... General description: Dish uses include large-scale colony-counting ... with PBA Flexys TM automated colony ... is a new product number, created to ... no availability yet, please order under the ...
Mouse monoclonal [7B9] to beta II Tubulin ( Abpromise for all tested applications). Antigen: Synthetic peptide, CEEEEGEDEA found at the c-terminus of beta II tubulin. Entrez GeneID: 10383 ...
Biology Products: